Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: ddl who wrote (320)	8/2/2005 6:16:16 PM
From: Pluvia	Read Replies (1) \| Respond to of 377

<<<<you appear to be dancing around the questions. ask a question, i'll answer. so far, you only provide your opinions, which seem to be based on nothing but wishful thinking. >>>>>>>I must say that on one of Vasogen PII trials, the results were very dramatic. You should re-read them. which trial specifically? there's only two published... for example, VSGN's POAD PII trial: Mcgrath et al. Eur J Vas Endovasc Surgery 23, 381-387; 2002 specifically page 386: "Endothelium dysfunction occurs in patients with diabetes and arterial disease. It is possible that this damage may become to severe for IMT to be effective. Thus a poorer outcome may be expected from patients with severe arterial disease, with diabetes or both." hmmmm... that's not so encouraging now is it? FYI, diabetics and patients with 'severe arterial disease' comprise the VAST majority of the patient population who seek treatment for PAOD; i.e. - VSGN's target market.... non-diabetic patients and patients without severe arterial disease rarely know they have PAOD, and rarely seek or get treatment. bit of a tough market there i'd say.....